We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA ‘Confident’ That Interchangeable Insulin Will Be Available After March 2020
FDA ‘Confident’ That Interchangeable Insulin Will Be Available After March 2020
Approved NDAs for certain biological products will be deemed to be biologics licenses under new FDA policies beginning March 2020, allowing the products to compete under the biosimilars pathway and potentially lower drug costs.